The latest announcement is out from Rapid Micro Biosystems ( (RPID) ).
On March 4, 2025, Rapid Micro Biosystems updated its corporate presentation for investor meetings, highlighting its strategic priorities and collaborations. The company reported significant revenue growth in 2024, driven by new customer wins and global system placements, and announced collaborations with Merck KGaA and Lonza to enhance product offerings and operational efficiencies. These developments are expected to improve gross margins and support long-term growth, with a revenue target of at least $32 million for 2025.
More about Rapid Micro Biosystems
Rapid Micro Biosystems operates in the pharmaceutical manufacturing industry, focusing on automated microbial quality control testing. The company offers products such as the Growth Direct platform, which aims to modernize microbial quality control processes. Their market focus includes pharmaceutical, personal care, medical device, cosmetics, and food & beverage sectors.
YTD Price Performance: 211.22%
Average Trading Volume: 451,607
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $131.3M
See more data about RPID stock on TipRanks’ Stock Analysis page.